Kasabach-Merritt Syndrome (KMS) is a rare and complex disorder that affects both children and adults. It is a combination of two conditions: thrombocytopenia (low platelet count) and vascular malformation (abnormal blood vessel growth). KMS is often referred to as a “mystery” because it is difficult to diagnose and treat. Despite its rarity, KMS is a serious condition that can lead to life-threatening complications if left untreated. Fortunately, in recent years, researchers have begun to unravel the mystery of KMS, making progress toward finding a cure.
Kasabach-Merritt Syndrome was first described in 1940 by Dr. Henry Kasabach and Dr. Merritt. They observed that patients with KMS had a low platelet count and large, abnormal blood vessels. It was not until the 1980s that researchers began to understand the underlying cause of the syndrome. It was discovered that KMS is caused by a disruption in the balance between the body’s platelets and the growth of abnormal blood vessels.
The symptoms of KMS vary from person to person, but the most common symptoms include low platelet count, excessive bleeding, and pain or swelling in the affected area. Other symptoms may include fever, fatigue, and weight loss. In some cases, KMS can cause life-threatening complications such as organ failure or stroke.
KMS can be difficult to diagnose due to its rarity and the fact that its symptoms can be similar to other conditions. To diagnose KMS, doctors will typically order a complete blood count, which measures the number of platelets in the blood. Doctors may also order an ultrasound or MRI to check for the presence of abnormal blood vessels. In some cases, a biopsy may be needed to confirm the diagnosis.
The main goal of treating KMS is to reduce the number of platelets and reduce the size of the abnormal blood vessels. Treatment typically involves a combination of medications, including anticoagulants to reduce the platelet count, and corticosteroids to reduce inflammation. In some cases, surgery may be necessary to remove the abnormal blood vessels.
Despite advances in treatment, there is still no cure for KMS. Researchers are actively searching for new treatments and a potential cure. Scientists are exploring the use of gene therapy to target the underlying cause of the syndrome. In addition, researchers are investigating the use of stem cell therapy to repair damaged blood vessels and restore normal platelet levels.
Kasabach-Merritt Syndrome is a rare and complex disorder that can lead to life-threatening complications if left untreated. Fortunately, in recent years, researchers have begun to unravel the mystery of KMS, making progress toward finding a cure. While there is currently no cure, researchers are actively searching for new treatments and a potential cure. With continued research, we may one day be able to find a cure for KMS and help those affected lead healthier, more fulfilling lives.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
1.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation